disease neurofibromatosis type 2 - HEALTHIES
The US Food and Drug Administration (FDA) has approved mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.) for certain adult and pediatric patients with neurofibromatosis type 1 (NF1). Specifically ... Learning that your child has neurofibromatosis type 1 (NF1) comes with a range of emotions and practical concerns.
Understanding the Context
While many people diagnosed with NF1 will have a normal life expectancy, the ... EurekAlert!: An international study validates the efficacy of a drug in adults with neurofibromatosis type 1 An international study validates the efficacy of a drug in adults with neurofibromatosis type 1 Nasdaq: FDA Approves SpringWorks Therapeutics' GOMEKLI for Treatment of Neurofibromatosis Type 1 in Adults and Children FDA Approves SpringWorks Therapeutics' GOMEKLI for Treatment of Neurofibromatosis Type 1 in Adults and Children MedPage Today: MEK Inhibitor Scores Big Win in Adults, Children With Neurofibromatosis Type 1 Almost half of adults and children with neurofibromatosis type 1 (NF1) responded to the investigational MEK inhibitor mirdametinib, a large multicenter study of the rare condition showed. Overall, 53 ... MEK Inhibitor Scores Big Win in Adults, Children With Neurofibromatosis Type 1 The FDA has approved selumetinib (Koselugo, AstraZeneca) for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
Image Gallery
Key Insights
Selumetinib, an oral kinase ... Nasdaq: AstraZeneca: Alexion's Koselugo Gets FDA Approval For Adults With Neurofibromatosis Type 1 AstraZeneca: Alexion's Koselugo Gets FDA Approval For Adults With Neurofibromatosis Type 1